JP4442912B2 - Composition for external use - Google Patents
Composition for external use Download PDFInfo
- Publication number
- JP4442912B2 JP4442912B2 JP2007087761A JP2007087761A JP4442912B2 JP 4442912 B2 JP4442912 B2 JP 4442912B2 JP 2007087761 A JP2007087761 A JP 2007087761A JP 2007087761 A JP2007087761 A JP 2007087761A JP 4442912 B2 JP4442912 B2 JP 4442912B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- acid
- adenosine
- hair
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 76
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 126
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 63
- 229960005305 adenosine Drugs 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 210000004761 scalp Anatomy 0.000 claims description 26
- 210000004209 hair Anatomy 0.000 claims description 24
- 229920006317 cationic polymer Polymers 0.000 claims description 17
- 230000003779 hair growth Effects 0.000 claims description 14
- 150000007524 organic acids Chemical class 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 125000002091 cationic group Chemical group 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- JTHZUSWLNCPZLX-UHFFFAOYSA-N 6-fluoro-3-methyl-2h-indazole Chemical compound FC1=CC=C2C(C)=NNC2=C1 JTHZUSWLNCPZLX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 229920006322 acrylamide copolymer Polymers 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims description 2
- 229940008406 diethyl sulfate Drugs 0.000 claims description 2
- GQOKIYDTHHZSCJ-UHFFFAOYSA-M dimethyl-bis(prop-2-enyl)azanium;chloride Chemical compound [Cl-].C=CC[N+](C)(C)CC=C GQOKIYDTHHZSCJ-UHFFFAOYSA-M 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000013329 compounding Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- -1 trimethylammonio Chemical group 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003303 reheating Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 229960002326 bithionol Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 150000003538 tetroses Chemical class 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N γ Benzene hexachloride Chemical compound ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
本発明は、優れた育毛効果や血行促進効果を有するアデノシンの低温下における安定性を向上させた外用組成物に関する発明である。 The present invention relates to a composition for external use in which the stability of adenosine having an excellent hair growth effect and blood circulation promoting effect is improved at low temperatures.
アデノシンは、優れた育毛効果や血行促進効果を、頭皮頭髪や、肌上において発揮する成分として、育毛料や皮膚外用剤等への配合が行われている(特許文献1〜9)。しかしながら、アデノシンは水やアルコールへの溶解性に問題があり、また溶解性に温度依存性が強く認められ、高温や室温で溶解しても低温では過飽和状態になってしまい、時間が経つと析出・沈殿が認められる。よって、現状において製品レベルでの実用的なアデノシンの配合量は、せいぜい製品の0.8質量%程度であり、これを超えるレベルでのアデノシンの配合手段が求められている。なお、下記特許文献1〜9には、アデノシンを組成物の1%以上配合した例も開示されているが、いずれも常温(25℃程度)での配合であり、低温(5〜−20℃)下においてアデノシンを同1%以上配合した例はない。 Adenosine has been incorporated into hair-growth agents, skin external preparations, and the like as components that exhibit excellent hair-growth and blood circulation promoting effects on the scalp and hair and on the skin (Patent Documents 1 to 9). However, adenosine has a problem in solubility in water and alcohol, and the temperature dependence of the solubility is strongly recognized. Even if it is dissolved at high temperature or room temperature, it becomes supersaturated at low temperature, and precipitates over time.・ Precipitation is observed. Therefore, at present, the amount of practical adenosine blended at the product level is at most about 0.8% by mass of the product, and a means for blending adenosine at a level exceeding this is required. In addition, although the following patent documents 1-9 disclose the example which mix | blended 1% or more of the composition with adenosine, all are the mixing | blending at normal temperature (about 25 degreeC), and low temperature (5--20 degreeC). ) There is no example in which adenosine is blended at 1% or more.
なお、アデノシンのリン酸塩等のアデノシンを塩の形態とすることで、比較的大量の配合自体は可能であるが(例えば、特許文献4)、アデノシンの塩では、毛乳頭細胞等に存在するアデノシン受容体への直接的な作用が低下するために、アデノシンに本来的に期待する、その配合量に見合った薬理効果を発揮することが困難となる。また、本願の出願人の出願でアデノシンを10%配合した例(特許文献7の実施例2)も開示されているが、これは短時間でのみアデノシンの溶解状態が維持されるものであり、経時的な使用に適したものではない。当該特許文献7の実施例の試験薬剤は、養毛試験期間中は繰り返し調製している。
本発明が解決すべき課題は、上述のように優れた効能を有するアデノシンを、低温状態下であっても経時的安定性が担保された状態とする手段を提供することにある。 The problem to be solved by the present invention is to provide means for making adenosine having excellent efficacy as described above a state in which stability over time is ensured even under low temperature conditions.
本発明者は、上記の課題の解決に向けて鋭意検討を行った結果、アデノシンと、分子量8万〜500万でありカチオンモノマー比が10〜100質量%のカチオン性高分子と、低級アルコールと、有機酸を、概ね特定質量範囲にて共存させることにより、組成物に対して1〜2%という高濃度でアデノシンの配合を行っても、製品を調製する際の溶解性が良好であり、当該製品の低温状態下における経時的な安定性が担保されることを見出し、本発明を完成した。 As a result of intensive studies aimed at solving the above problems, the present inventor has found that adenosine, a cationic polymer having a molecular weight of 80,000 to 5,000,000 and a cationic monomer ratio of 10 to 100% by mass, a lower alcohol, In addition, by coexisting an organic acid in a specific mass range, even when adenosine is blended at a high concentration of 1 to 2% with respect to the composition, the solubility when preparing the product is good. The present invention was completed by finding that the stability of the product over time under low temperature conditions is ensured.
すなわち、本発明は、下記(1)〜(4)の特徴を有する外用組成物(以下、本組成物ともいう)を提供する発明である。
(1)アデノシンを組成物全体の1.0〜2.0質量%含有する。
(2)分子量8万〜500万でありカチオンモノマー比が10〜100質量%のカチオン性高分子を組成物全体の0.001〜5質量%含有する。
(3)エタノール、メタノール、エチレングリコール、又は、イソプロピルアルコールを、組成物全体の35.0〜65.0質量%含有する。
(4)有機酸を含有する。
That is, this invention is an invention which provides the external composition (henceforth this composition) which has the characteristics of following (1)-(4).
(1) Adenosine is contained in an amount of 1.0 to 2.0% by mass based on the entire composition.
(2) A cationic polymer having a molecular weight of 80,000 to 5,000,000 and a cationic monomer ratio of 10 to 100% by mass is contained in an amount of 0.001 to 5% by mass of the entire composition.
(3) 35.0-65.0 mass% of ethanol, methanol, ethylene glycol, or isopropyl alcohol of the whole composition is contained.
(4) Contains an organic acid.
本組成物は、アデノシンを配合して、その効能を肌上又は頭皮頭髪において活用することが可能な目的又は形態の外用組成物として用いることが可能である。具体的には、アデノシンの優れた育毛効果による頭皮頭髪用組成物(典型的には育毛料)や、同じく優れた血行促進効果を発揮し得る皮膚外用剤等が挙げられる。 This composition can be used as an external composition for the purpose or form in which adenosine is blended and its effect can be utilized on the skin or scalp and hair. Specifically, a composition for scalp and scalp hair (typically a hair restorer) with an excellent hair growth effect of adenosine, a skin external preparation that can also exhibit an excellent blood circulation promoting effect, and the like can be mentioned.
本発明により、外用組成物においてアデノシンを高濃度配合しつつ(組成物全体の1.0〜2.0質量%)、低温状態下でも当該外用組成物の長期保存が可能となる。 According to the present invention, the composition for external use can be stored for a long period of time even under a low temperature condition while blending a high concentration of adenosine in the composition for external use (1.0 to 2.0% by mass of the whole composition).
[本組成物の配合成分]
本組成物の必須成分の一つは、効能成分として配合するアデノシンである。アデノシンは、リボヌクレオシドの一つで塩基部分にプリン誘導体であるアデニンを含むものである。
[Composition ingredients of this composition]
One of the essential components of this composition is adenosine to be blended as an active ingredient. Adenosine is one of ribonucleosides and contains adenine which is a purine derivative in the base part.
本組成物に配合するアデノシンは、試薬として市販されているものを使用することもできる。本組成物におけるアデノシンの配合量は、組成物全体の1.0〜2.0質量%である。同1.0質量%未満の配合も可能であるが、他の組成でも本組成物と同等の低温保存性を発揮させることも可能であり、本組成物の製剤上の利点が十分に顕れない。また、同2.0質量%を超えると、低温でのアデノシンの析出を十分に抑制することが困難となる傾向がある。 As adenosine to be blended in the present composition, a commercially available reagent can be used. The compounding quantity of adenosine in this composition is 1.0-2.0 mass% of the whole composition. The blending of less than 1.0% by mass is also possible, but other compositions can exhibit the same low temperature storage stability as the present composition, and the formulation advantages of the present composition are not fully manifested. . Moreover, when it exceeds 2.0 mass%, there exists a tendency for it to become difficult to fully suppress precipitation of adenosine at low temperature.
本組成物には、分子量8万〜500万でありカチオンモノマー比が10〜100質量%のカチオン性高分子を1種以上配合する。当該分子量が8万未満であると、アデノシンの低温での析出を十分に抑えることが出来ず、500万を超えると、使用性にポリマーのハリ感が強く出てしまうため、好ましくない。 In the present composition, one or more cationic polymers having a molecular weight of 80,000 to 5,000,000 and a cationic monomer ratio of 10 to 100% by mass are blended. If the molecular weight is less than 80,000, precipitation of adenosine at a low temperature cannot be sufficiently suppressed, and if it exceeds 5 million, the polymer feels strong in usability, which is not preferable.
このようなカチオン性高分子としては、例えば、ポリ塩化ジメチルメチレンピペリジニウム、塩化ジメチルジアリルアンモニウム・アクリルアミド共重合体、塩化O−[2−ヒドロキシ−3−(トリメチルアンモニオ)プロピル]ヒドロキシエチルセルロース、ビニルピロリドン・メタクリル酸N,N−ジメチルアミノエチル・アクリル酸ステアリル・ジアクリル酸トリプロピレングリコール共重合体、ビニルピロリドン・N,N−ジメチルアミノエチルメタクリル酸共重合体ジエチル硫酸塩等が挙げられる。当該カチオン性高分子の本組成物における配合量は、カチオン性高分子の種類等によって適宜選択することが可能であり、組成物全体の0.001〜5.0質量%配合することが好ましい。カチオン性高分子の配合量が、組成物全体の0.001質量%未満では、カチオン性高分子を配合したことによるアデノシンの低温安定性のさらなる向上効果が十分でない傾向があり、同5.0質量%を超えて配合すると、乾燥時のべたつきや皮膜感が著しくなり、使用性に問題を生じる傾向がある。 Examples of such cationic polymer include polydimethylmethylenepiperidinium chloride, dimethyldiallylammonium chloride / acrylamide copolymer, O- [2-hydroxy-3- (trimethylammonio) propyl] hydroxyethylcellulose chloride, Examples thereof include vinylpyrrolidone / N, N-dimethylaminoethyl methacrylate / stearyl acrylate / tripropylene glycol diacrylate copolymer, vinylpyrrolidone / N, N-dimethylaminoethyl methacrylate copolymer diethyl sulfate, and the like. The blending amount of the cationic polymer in the present composition can be appropriately selected depending on the kind of the cationic polymer and the like, and is preferably blended in an amount of 0.001 to 5.0% by mass of the entire composition. When the blending amount of the cationic polymer is less than 0.001% by mass of the whole composition, the effect of further improving the low temperature stability of adenosine by blending the cationic polymer tends to be insufficient. When the blending amount exceeds 5% by mass, the stickiness and film feeling at the time of drying become remarkable, and there is a tendency to cause problems in usability.
上記のカチオン性高分子の市販品としては、例えば、マーコート100(CALGON Co.製)マーコート550(CALGON Co.製)、CGポリマー(大阪有機化学工業株式会社製)、ガフコート755−S(日本精化社製)、ポリマーJR−400(ユニオン・カーバイド日本株式会社製)等が挙げられる。 Commercially available products of the above cationic polymers include, for example, Marcote 100 (manufactured by CALGON Co.), Marquat 550 (manufactured by CALGON Co.), CG polymer (manufactured by Osaka Organic Chemical Industry Co., Ltd.), Guff Coat 755-S (Nihonsei) Chemical JR), polymer JR-400 (Union Carbide Japan Co., Ltd.) and the like.
本組成物に配合する低級アルコールは、エタノール、メタノール、エチレングリコール、イソプロピルアルコール等が挙げられるが、安全性や実用性等の面からエタノールを用いることが好適である。市販品としては一般アルコール95度合成(日本アルコール販売株式会社)等が挙げられる。本組成物におけるエタノール等の低級アルコールの配合量は、組成物全体の35.0〜65.0質量%であり、好適には同40.0〜60.0質量%である。この配合量が組成物全体の35.0質量%未満ではアデノシンの低温での析出が認められ、同65.0質量%を超えて配合すると、アデノシンの溶解性が低下する。なお、本明細書及び特許請求の範囲における低級アルコールの配合量は、100%アルコール換算として表示する。 Examples of the lower alcohol to be blended in the present composition include ethanol, methanol, ethylene glycol, isopropyl alcohol, etc., but it is preferable to use ethanol from the viewpoints of safety and practicality. Commercially available products include general alcohol 95-degree synthesis (Japan Alcohol Sales Co., Ltd.) and the like. The compounding quantity of lower alcohols, such as ethanol in this composition, is 35.0-65.0 mass% of the whole composition, and is 40.0-60.0 mass% suitably. If the blending amount is less than 35.0% by mass of the whole composition, precipitation of adenosine at a low temperature is observed, and if it exceeds 65.0% by mass, the solubility of adenosine is lowered. In addition, the compounding quantity of the lower alcohol in this specification and a claim is displayed as 100% alcohol conversion.
本組成物に配合する有機酸は、従来から外用組成物に有機酸として配合されているものを適宜選択することが可能であり、リンゴ酸、クエン酸、乳酸、グルタミン酸、ピロリドンカルボン酸、蟻酸、酢酸、安息香酸、ベンゼンスルホン酸、コハク酸等が挙げられる。有機酸の本組成物における配合量は、組成物全体の0.0001〜1.0質量%の範囲で配合することが好ましい。同配合量が0.0001質量%未満では、アデノシンの溶解性が十分に良好にならず、1.0質量%を超えて配合すると、使用時のべたつきや、頭皮への刺激が著しくなる傾向が認められる。 The organic acid to be blended in the composition can be appropriately selected from those conventionally blended as an organic acid in a composition for external use, malic acid, citric acid, lactic acid, glutamic acid, pyrrolidone carboxylic acid, formic acid, Examples include acetic acid, benzoic acid, benzenesulfonic acid, and succinic acid. It is preferable to mix | blend the compounding quantity in this composition of organic acid in 0.0001-1.0 mass% of the whole composition. When the blending amount is less than 0.0001% by mass, the solubility of adenosine is not sufficiently good. When the blending amount exceeds 1.0% by mass, the stickiness during use and the irritation to the scalp tend to be remarkable. Is recognized.
有機酸の市販品としては、例えば、DL-リンゴ酸フソウ S(扶桑化学工業株式会社製)、琥珀酸(武田キリン食品株式会社製)、乳酸一級(第一製薬株式会社製)、化粧品用L−グルタミン酸(味の素株式会社)等が挙げられる。 Examples of commercially available organic acids include DL-malic acid fuso S (manufactured by Fuso Chemical Co., Ltd.), oxalic acid (manufactured by Takeda Kirin Foods Co., Ltd.), lactic acid first grade (manufactured by Daiichi Pharmaceutical Co., Ltd.), L for cosmetics -Glutamic acid (Ajinomoto Co., Inc.) etc. are mentioned.
[本組成物の形態]
上述したように、本組成物の主要な形態として、アデノシンの育毛効果を活用した、育毛料に代表される頭皮頭髪用組成物と、同血行促進効果を活用した皮膚外用剤が挙げられる。
[Form of the present composition]
As described above, the main forms of the present composition include a scalp hair composition represented by a hair-growth material utilizing the hair-growth effect of adenosine, and a topical skin preparation utilizing the blood circulation promoting effect.
(1)頭皮頭髪用組成物(以下、本頭皮頭髪用組成物ともいう)
一般に、脱毛の原因としては、毛包や皮脂腺等の器官における男性ホルモンの活性化、毛乳頭や毛包への血流量の低下、皮脂の分泌過剰、過酸化物の生成等による頭皮の異常、栄養不良等が考えられている。
(1) Composition for scalp and hair (hereinafter also referred to as composition for scalp and hair)
In general, the causes of hair loss include activation of male hormones in organs such as hair follicles and sebaceous glands, decreased blood flow to hair papilla and hair follicles, excessive secretion of sebum, abnormalities of the scalp due to the production of peroxides, Malnutrition is considered.
このため、従来の育毛料には、これらの原因を取り除き、又は、軽減する作用を持つ成分が一般に配合されている。その中でも、アデノシンには優れた血行促進効果が認められ、この血行促進効果と相まって、優れた脱毛防止作用や発毛促進作用等の育毛作用が認められている。現在、アデノシンは、育毛料等の頭皮頭髪用組成物に積極的に配合されている。 For this reason, the conventional hair restorer generally contains a component having an action of removing or reducing these causes. Among them, adenosine has an excellent blood circulation promoting effect, and in combination with this blood circulation promoting effect, an excellent hair growth action such as a hair loss preventing action and a hair growth promoting action is recognized. Currently, adenosine is actively blended in compositions for scalp and hair, such as hair growth agents.
本組成物を頭皮頭髪用組成物とすることにより、組成物全体の1.0〜2.0質量%という高濃度のアデノシンを含有させることにより、その優れた血行促進効果により、頭皮における血行を促進させ、脱毛防止作用、発毛促進作用等を十分に発揮し、かつ、低温における経時的安定性に優れる頭皮頭髪用組成物を得ることができる。 By making this composition into a composition for scalp and scalp hair, by containing a high concentration of adenosine of 1.0 to 2.0% by mass of the whole composition, blood circulation in the scalp is reduced due to its excellent blood circulation promoting effect. It is possible to obtain a composition for scalp and hair that is promoted, exhibits a hair loss preventing action, a hair growth promoting action, etc., and has excellent temporal stability at low temperatures.
なお、本発明において「育毛」とは、脱毛防止作用,発毛促進作用等を包含する概念で使用される。 In the present invention, “hair growth” is used in a concept including a hair loss preventing effect, a hair growth promoting effect and the like.
本頭皮頭髪用組成物には、一般的に頭皮頭髪用組成物に配合され得る育毛成分を、本発明による低温安定効果とアデノシンによる効能を明らかに損なわない範囲で配合することができる。 In the composition for scalp and scalp hair, a hair-restoring ingredient that can generally be blended in the composition for scalp and hair can be blended in a range that does not clearly impair the low-temperature stability effect and the effect of adenosine according to the present invention.
例えば、抗菌剤として、ヒノキチオール、ヘキサクロロフェン、ベンザルコニウムクロリド、セチルピリジニウムクロリド、ウンデシレン酸、トリクロロカルバニリド、ビチオノール等を配合することができる。 For example, as an antibacterial agent, hinokitiol, hexachlorophene, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, bithionol, and the like can be blended.
また、薬剤成分として、ニコチン酸アミド、ニコチン酸ベンジル、ビタミンE又はその誘導体、例えばビタミンEアセテート、センブリエキス、塩化カルプロニウム、アセチルコリン誘導体等の血管拡張剤;セファランチン等の皮膚機能亢進剤;グリチルレチン酸又はその誘導体、紫根エキス等の消炎剤;エストラジオール、エストロン等の女性ホルモン剤;セリン、メチオニン、アルギニン等のアミノ酸類;ビタミンA、ビタミンB 1 、ビタミンB 6 、ビオチン、パントテン酸又はその誘導体等のビタミン類;アデニン、シトシン、チミン、グアニン等の核酸等を配合することができる。 Further, as drug components, nicotinamide, benzyl nicotinate, vitamin E or derivatives thereof, for example, vasodilators such as vitamin E acetate, assembly extract, carpronium chloride, acetylcholine derivatives; skin function enhancers such as cephalanthin; glycyrrhetic acid or Derivatives, anti-inflammatory agents such as purple root extract; female hormone agents such as estradiol and estrone; amino acids such as serine, methionine, and arginine; vitamins such as vitamin A, vitamin B 1 , vitamin B 6 , biotin, pantothenic acid, and derivatives thereof Kinds: Nucleic acids such as adenine, cytosine, thymine and guanine can be blended.
さらに、必要に応じて、サリチル酸、亜鉛又はその誘導体、乳酸アルキルエステル等の薬剤、メントール等の清涼剤を配合することができる。 Furthermore, if necessary, a chemical such as salicylic acid, zinc or a derivative thereof, a lactic acid alkyl ester, or a refreshing agent such as menthol can be blended.
さらに、必要に応じて保湿剤を1種以上配合することができる。糖系保湿剤として、例えば、グリセリン、ジグリセリン、テトロース、ペントース、ヘキソース、ヘプトース、テトリット、ペンチット、へキシット、エリスリトール、マルチトール、マンニトール、ソルビトール、キシリトール、ヒアルロン酸、ポリオキシエチレンメチルグルコシド等が挙げられる。また、糖系保湿剤以外の保湿剤としては、プロピレングリコール、ジプロピレングリコール、ポリエチレングリコール、ブチレングリコール、ポリブチレングリコール、ポリオキシエチレン−ポリオキシプロピレン−ジメチルエーテル等が挙げられる。保湿剤中における糖系保湿剤の含有量が保湿剤全体の25.0〜100質量%であることが好適である。 Furthermore, 1 or more types of moisturizers can be mix | blended as needed. Examples of sugar humectants include glycerin, diglycerin, tetrose, pentose, hexose, heptose, tetrit, pentite, hexit, erythritol, maltitol, mannitol, sorbitol, xylitol, hyaluronic acid, polyoxyethylene methyl glucoside, etc. It is done. Examples of the humectant other than the sugar-type humectant include propylene glycol, dipropylene glycol, polyethylene glycol, butylene glycol, polybutylene glycol, and polyoxyethylene-polyoxypropylene-dimethyl ether. It is preferable that the content of the sugar-based moisturizing agent in the moisturizing agent is 25.0 to 100% by mass of the entire moisturizing agent.
なお、本頭皮頭髪用組成物には、上述した諸成分の他に、本発明による低温安定効果とアデノシンによる効能を明らかに損なわない範囲で、通常、外用組成物に配合され得る他の成分を、例えば、油分、界面活性剤、増粘剤、紫外線吸収剤、酸化防止剤、防腐剤、香料、色素、水等の溶媒、の中から必要に応じて適宜配合することができる。 In addition to the various components described above, the present scalp and hair composition usually contains other components that can be blended in the composition for external use as long as the low-temperature stability effect and the efficacy of adenosine according to the present invention are not clearly impaired. For example, an oil, a surfactant, a thickener, an ultraviolet absorber, an antioxidant, a preservative, a fragrance, a pigment, water, and other solvents can be appropriately blended as necessary.
本頭皮頭髪用組成物は、目的とする剤型に応じて常法により製造することができる。その採り得る剤型は任意であり、例えば、液状、乳液、軟膏、クリーム、ゲル、エアゾール等、外用に適用可能な剤型のものであればいずれでもよい。また、その製品形態も任意であり、例えば、トニック、スカルプトリートメント、スカルプローションの形態で用いられ得る。 The composition for scalp and scalp hair can be produced by a conventional method according to the intended dosage form. The dosage form which can be taken is arbitrary, for example, any liquid dosage form can be applied for external use such as liquid, emulsion, ointment, cream, gel, aerosol and the like. Moreover, the product form is also arbitrary, for example, it can be used in the form of a tonic, a scalp treatment, or a scalp lotion.
(2)皮膚外用剤
上記の頭皮頭髪用組成物の他に、本組成物を皮膚外用剤として用いることができる。すなわち、その優れた血行促進作用が、アデノシンの高濃度配合により、肌上において十分に発揮され、かつ、低温安定性が向上した皮膚外用剤が提供される。
(2) External preparation for skin In addition to the above-mentioned composition for scalp and hair, this composition can be used as an external preparation for skin. That is, a skin external preparation that exhibits its excellent blood circulation promoting action sufficiently on the skin and has improved low-temperature stability by providing a high concentration of adenosine is provided.
当該皮膚外用剤には、本発明による低温安定効果とアデノシンによる効能を明らかに損なわない範囲で、一般的に外用組成物に配合され得る他の成分を必要に応じて配合することができる。例えば、上述した抗菌剤、薬剤成分、清涼剤、保湿剤、油分、界面活性剤、増粘剤、紫外線吸収剤、酸化防止剤、防腐剤、香料、色素、水等の溶媒、の中から必要に応じて適宜配合することができる。 In the external preparation for skin, other components that can be generally blended in the composition for external use can be blended as needed within a range that does not clearly impair the low-temperature stability effect and the effect of adenosine according to the present invention. For example, necessary from among the above-mentioned antibacterial agents, drug components, refreshing agents, humectants, oils, surfactants, thickeners, UV absorbers, antioxidants, preservatives, fragrances, pigments, water and other solvents. Can be appropriately blended depending on
当該皮膚外用剤は、目的とする剤型に応じて常法により製造することができる。その採り得る剤型は任意であり、例えば、液状、乳液、軟膏、クリーム、ゲル、エアゾール等、外用に適用可能な剤型のものであればいずれでもよい。また、その製品形態も任意である。 The said external preparation for skin can be manufactured by a conventional method according to the target dosage form. The dosage form which can be taken is arbitrary, for example, any liquid dosage form can be applied for external use such as liquid, emulsion, ointment, cream, gel, aerosol and the like. Moreover, the product form is also arbitrary.
次に、実施例を挙げて本発明を更に具体的に説明するが、本発明の範囲が、これらの実施例のみに限定されるものではない。なお、以下の実施例において、配合量は、配合対象に対する質量%であり、アデノシン類については、固形分量として表示している。 Next, the present invention will be described more specifically with reference to examples. However, the scope of the present invention is not limited only to these examples. In addition, in the following Examples, a compounding quantity is the mass% with respect to the compounding object, and about adenosine, it is displayed as a solid content.
〔実施例1〜11、比較例1〜11〕
表1〜3に示す処方で、下記の製造方法に基づいて育毛料を調製し、さらに、下記の試験により、これらの頭皮頭髪用ローションのアデノシン溶解性(25℃)及び0℃での低温安定性を検討した。その試験結果を併せて表1〜3に示す。
[Examples 1-11, Comparative Examples 1-11]
In the formulations shown in Tables 1 to 3, hair growth preparations were prepared based on the following production method, and further, the following tests revealed that these scalp and hair lotions had adenosine solubility (25 ° C.) and stable at 0 ° C. The sex was examined. The test results are also shown in Tables 1 to 3.
〔製造方法〕
エタノールに、香料を溶解させた(エタノール部)。次に、精製水に、有機酸及びカチオン性高分子を溶解させ、これを、前記エタノール部に加えた後、アデノシンを添加し、攪拌することにより、透明液状のローションを得た。ここまでは、25℃下にて行った。なお、アデノシンを溶かすことができなかった比較例については、液を加温(30〜50℃)して、一旦溶解させた。
〔Production method〕
A perfume was dissolved in ethanol (ethanol part). Next, an organic acid and a cationic polymer were dissolved in purified water, and after adding this to the ethanol part, adenosine was added and stirred to obtain a transparent liquid lotion. Up to this point, the test was performed at 25 ° C. In addition, about the comparative example which was not able to melt | dissolve adenosine, the liquid was heated (30-50 degreeC) and once dissolved.
[試験方法と評価基準]
上記の製造工程は、常温(25℃下)にて行われ、その際、アデノシンが完全に溶解したものについては「○」として評価し、一部のアデノシンが溶解せずに残り、完全溶解には再加熱が必要であったものについては「△」として評価し、ほとんどのアデノシンが溶解せずに、完全溶解には再加温が必要であったものについては「×」として評価した。
[Test methods and evaluation criteria]
The above manufacturing process is performed at room temperature (under 25 ° C.). At that time, those in which adenosine is completely dissolved are evaluated as “◯”, and a part of adenosine remains undissolved and completely dissolved. Was evaluated as “Δ” for those that required reheating, and “x” for those that did not dissolve most of the adenosine but required reheating for complete dissolution.
また、このようにしてアデノシンを完全溶解させた試験品を蓋付きのバイアルに封入して、0℃下で1ヶ月静置して、1ヶ月後のアデノシンの結晶の析出について、試験開始時と同様に全く変化無くアデノシンが溶解していたものを「○」として評価し、わずかにアデノシンの結晶が析出したものを「△」として評価し、アデノシンの結晶の析出が一見して判別可能であるものを「×」として評価した。これらの評価結果についても、表1〜3にて示した。 In addition, the test product in which adenosine was completely dissolved in this manner was sealed in a vial with a lid, and allowed to stand at 0 ° C. for 1 month, and the precipitation of adenosine crystals after 1 month was measured at the start of the test. Similarly, it was evaluated as “◯” when adenosine was dissolved without any change, and evaluated as “△” when a slight amount of adenosine crystals were precipitated, so that the precipitation of adenosine crystals can be discriminated at a glance. Things were evaluated as “x”. These evaluation results are also shown in Tables 1 to 3.
表1の結果より、ポリマーJRの配合により1.5%まで常温で溶解することが出来、アデノシン2.0%配合まで低温の経時安定性も良好であった。 From the results in Table 1, it was possible to dissolve at room temperature up to 1.5% by blending polymer JR, and the stability over time at low temperature was also good up to 2.0% adenosine.
表2の結果より、カチオン単分子や分子量が低い(8万以下)のカチオン性高分子では、低温でアデノシンの析出が認められたが、その他のカチオン高分子においては低温の経時安定性は良好であった。また、いずれの例でも、25℃でのアデノシンの溶解性は良好「○」であった。 From the results shown in Table 2, adenosine precipitation was observed at low temperatures in cationic monomolecules and cationic polymers with low molecular weight (80,000 or less), but other cationic polymers have good stability over time at low temperatures. Met. In all examples, the solubility of adenosine at 25 ° C. was good “◯”.
表3の結果より、アニオン、ノニオン高分子には低温安定性を向上させることはできず、カチオン性高分子を配合した場合のみ低温の経時安定性は良好であった。 From the results of Table 3, the low temperature stability could not be improved for the anion and nonionic polymers, and the low temperature stability with time was good only when the cationic polymer was blended.
表4の結果より、アルコールの量は多すぎても少なすぎてもアデノシンの溶解性及び低温安定性が悪化した。なお、出願後の手続補正により、表4に記載されていた比較例14は削除した。
From the results of Table 4, the solubility and low-temperature stability of adenosine deteriorated when the amount of alcohol was too much or too little. In addition, the comparative example 14 described in Table 4 was deleted by the procedure amendment after application.
表5の結果より、アデノシンはポリマーJR−400の配合で溶解性と安定性が向上するが、5%以上になると攪拌溶解が難しくなり溶かしきることが出来ない。 From the results of Table 5, adenosine improves the solubility and stability by blending polymer JR-400, but when it exceeds 5%, stirring and dissolution becomes difficult and cannot be completely dissolved.
表6の結果より、様々な有機酸でアデノシンの溶解性と低温安定性を向上させることができた。 From the results shown in Table 6, the solubility and low-temperature stability of adenosine could be improved with various organic acids.
以下、本願発明の処方例を実施例として記載する。これらの処方例において、アデノシンは、低温でも長期間安定して溶解していた。 Hereinafter, the formulation example of this invention is described as an Example. In these formulation examples, adenosine was stably dissolved for a long time even at a low temperature.
〔実施例23〕 育毛料
配合成分 配合量(質量%)
エタノール 60.0
ジプロピレングリコール 6.0
クエン酸 0.05
クエン酸ナトリウム 0.1
メントール 0.3
ビタミンEアセテート 0.3
アデノシン 2.0
マーコート550(CALGON Co.製) 0.3
精製水 残 余
<製造方法>
エタノールに、香料、薬剤を溶解させた(エタノール部)。次に、精製水に、有機酸及びカチオン性高分子を溶解させ、これを、前記エタノール部に加えた後、アデノシンを添加し、攪拌することにより、透明液状の育毛料を得た。
[Example 23] Hair restorer
Compounding component amount (% by mass)
Ethanol 60.0
Dipropylene glycol 6.0
Citric acid 0.05
Sodium citrate 0.1
Menthol 0.3
Vitamin E acetate 0.3
Adenosine 2.0
Marcote 550 (manufactured by CALGON Co.) 0.3
Purified water residue <Production method>
A fragrance | flavor and a chemical | medical agent were dissolved in ethanol (ethanol part). Next, an organic acid and a cationic polymer were dissolved in purified water, and after adding this to the ethanol part, adenosine was added and stirred to obtain a transparent liquid hair restorer.
〔実施例24〕 皮膚外用剤
配合成分 配合量(質量%)
ブチレングリコール 8.0
ポリオキシエチレン硬化ヒマシ油 0.5
エタノール 35.0
流動パラフィン 2.0
カルボマー 0.4
2−アミノ−2−メチル−1−プロパノール 0.1
アデノシン 1.4
ポリマーJR−400 1.0
(ユニオン・カーバイド日本株式会社製)
香料 適 量
精製水 残 余
<製造方法>
カルボマーを精製水に溶解させ、活性剤・精製水・油分を用い作った乳化パーツを添加し、攪拌した。これに香料を溶かしたエタノールと精製水を50℃まで加温しアデノシンを溶解させたものを添加し、最後にカルボマーを中和して増粘させ、皮膚外用剤を得た。
[Example 24] External preparation for skin
Compounding component amount (% by mass)
Butylene glycol 8.0
Polyoxyethylene hydrogenated castor oil 0.5
Ethanol 35.0
Liquid paraffin 2.0
Carbomer 0.4
2-Amino-2-methyl-1-propanol 0.1
Adenosine 1.4
Polymer JR-400 1.0
(Made by Union Carbide Japan Co., Ltd.)
Perfume Appropriate amount of purified water residue <Production method>
The carbomer was dissolved in purified water, and an emulsified part made using an activator, purified water, and oil was added and stirred. To this was added ethanol and purified water in which fragrance was dissolved up to 50 ° C. to dissolve adenosine, and finally the carbomer was neutralized and thickened to obtain a skin external preparation.
〔実施例25〕 ローション
配合成分 配合量(質量%)
ブチレングリコール 4.0
ヒドロキシプロピルセルロース 1.0
エタノール 40.0
アデノシン 1.6
CGポリマー(大阪有機化学工業株式会社製) 0.1
香料 適 量
精製水 残 余
<製造方法>
エタノールに、香料を溶解させた(エタノール部)。次に、精製水に、有機酸及びカチオン性高分子、ヒドロキシプロピルセルロースを溶解させ、これを、前記エタノール部に加えた後、アデノシンを添加し、攪拌することにより、ややとろみのある透明液状のローションを得た。
[Example 25] Lotion
Compounding component amount (% by mass)
Butylene glycol 4.0
Hydroxypropyl cellulose 1.0
Ethanol 40.0
Adenosine 1.6
CG polymer (Osaka Organic Chemical Industry Co., Ltd.) 0.1
Perfume Appropriate amount of purified water residue <Production method>
A perfume was dissolved in ethanol (ethanol part). Next, an organic acid, a cationic polymer, and hydroxypropyl cellulose are dissolved in purified water, and after adding this to the ethanol part, adenosine is added and stirred to obtain a slightly thick transparent liquid. Got lotion.
Claims (5)
(1)アデノシンを組成物全体の1.0〜2.0質量%含有する。
(2)分子量8万〜500万でありカチオンモノマー比が10〜100質量%のカチオン性高分子を組成物全体の0.001〜5質量%含有する。
(3)エタノール、メタノール、エチレングリコール、又は、イソプロピルアルコールを、組成物全体の35.0〜65.0質量%含有する。
(4)有機酸を含有する。 An external composition having the following features (1) to (4).
(1) Adenosine is contained in an amount of 1.0 to 2.0% by mass based on the entire composition.
(2) A cationic polymer having a molecular weight of 80,000 to 5,000,000 and a cationic monomer ratio of 10 to 100% by mass is contained in an amount of 0.001 to 5% by mass of the entire composition.
(3) 35.0-65.0 mass% of ethanol, methanol, ethylene glycol, or isopropyl alcohol of the whole composition is contained.
(4) Contains an organic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007087761A JP4442912B2 (en) | 2007-03-29 | 2007-03-29 | Composition for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007087761A JP4442912B2 (en) | 2007-03-29 | 2007-03-29 | Composition for external use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008247754A JP2008247754A (en) | 2008-10-16 |
JP4442912B2 true JP4442912B2 (en) | 2010-03-31 |
Family
ID=39973143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007087761A Active JP4442912B2 (en) | 2007-03-29 | 2007-03-29 | Composition for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4442912B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5689323B2 (en) * | 2010-10-21 | 2015-03-25 | 株式会社ファンケル | Cosmetics |
JP5931223B2 (en) * | 2013-01-21 | 2016-06-08 | 富士フイルム株式会社 | Skin preparation |
JPWO2022265054A1 (en) * | 2021-06-19 | 2022-12-22 | ||
CN118510489A (en) | 2022-02-03 | 2024-08-16 | 株式会社资生堂 | External composition for skin |
US20250073150A1 (en) | 2022-02-03 | 2025-03-06 | Shiseido Company, Ltd. | External-use skin preparation composition |
-
2007
- 2007-03-29 JP JP2007087761A patent/JP4442912B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008247754A (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5529539B2 (en) | Pharmaceutical composition | |
JPH10298027A (en) | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer material and stable solubilization of uric acid in the aqueous cosmetic composition | |
JP4442912B2 (en) | Composition for external use | |
JP2010163418A (en) | Cosmetic | |
JP2004307491A (en) | External preparation for skin containing heparin-like substance | |
JP5825053B2 (en) | Liquid-based sweat deodorant composition | |
JP2008247752A (en) | Composition for external application | |
CN108289839A (en) | Flushing-free chemical foam containing bent Fa Luoting and their purposes in treating acne | |
JP2023099672A (en) | External pharmaceutical composition | |
JP2001288043A (en) | Composition for scalp and hair | |
JP6832665B2 (en) | Aqueous formulation | |
JP5061984B2 (en) | Adapalene-containing external preparation composition | |
JP2018532773A (en) | Rinse-free chemical foam containing brimonidine and its use in the treatment of rosacea | |
JP5881879B1 (en) | External composition for improving acne vulgaris | |
HU226686B1 (en) | Semisolid pharmaceutical formulation containing dexketoprofen trometamol | |
JPH10279421A (en) | Preparation for external use for skin | |
JP7088750B2 (en) | Gel-like composition | |
JP5670008B2 (en) | Adapalene-containing external preparation composition | |
JP5109383B2 (en) | Adapalene-containing external preparation composition | |
JP2007210959A (en) | External composition for skin | |
JP7379094B2 (en) | External liquid | |
JPH111433A (en) | Tolnaftate-containing liquid agent | |
JP7467037B2 (en) | External Composition | |
JP2021123586A (en) | Topical pharmaceutical composition | |
JP2021123585A (en) | Topical pharmaceutical product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090730 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091006 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091202 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091202 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100107 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100108 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4442912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130122 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |